Rare diseases
Investigational molecules
Locations
419 Davis Drive Suite 100, 27560-7551, United States
Research activity is centered on pulmonary hypertension associated with interstitial lung disease (WHO Group 3), with interest in therapies for elevated pulmonary vascular pressure in the setting of chronic fibrotic and inflammatory lung disease. The sponsor’s clinical work reflects a focus on respiratory medicine and pulmonary vascular disease.
The clinical landscape is directed toward inhaled treatment approaches for symptoms and functional limitation linked to impaired lung circulation and reduced exercise capacity.
Liquidia Technologies Inc. runs clinical trials in conditions such as Interstitial lung disease, Pulmonary hypertension, among others.
Clinical trials run by this sponsor – those enrolling participants first.
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
